Previous 10 | Next 10 |
2023-03-07 08:37:46 ET Dermatology drug developer Novan ( NASDAQ: NOVN ) announced Tuesday that the FDA accepted its New Drug Application (NDA) for berdazimer gel, 10.3%, as a treatment for viral infection, molluscum contagiosum. The agency has granted January 05, 2024, as...
– FDA completes filing review of application with no filing issues identified – – New Chemical Entity (“NCE”) has potential to be the first FDA-approved prescription product for molluscum in the U.S. – – Novan’s commercia...
DURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the Virtual Investor 2023 Companies to Watch Event on Thurs...
- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that affects approximately 6 million people, most of them children ...
Summary Almost 60 percent of VEU’s AUM is invested in four sectors - ICT, financial, industrial, and healthcare. The fund generates decent yield and total returns. The strong US dollar, high sustained interest rate by the Fed, and slowing global economic growth are expected to we...
Novan ( NASDAQ: NOVN ) on Wednesday said its unit EPI Health had entered into a license agreement with Sato Pharmaceutical for Rhofade skin cream in Japan. Shares of NOVN rose 7.8% to $1.25 in premarket trading. Rhofade cream is a prescription medicine used on the skin to trea...
DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (...
Summary The IOO ETF is mostly just a value weighted US portfolio, with European exposures consisting primarily of healthcare and consumer staple exposures. We think geopolitics is the most important factor, and the US is in a great position eating Europe's lunch. America continues t...
– Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” o...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...